Saikrishna Gadde | UT Medical Center

Dr. Saikrishna Gadde

Claim this profile

University of Tennessee - Knoxville

Studies Bladder Cancer
Studies Skin Cancer
9 reported clinical trials
23 drugs studied

Area of expertise

1Bladder Cancer
Saikrishna Gadde has run 6 trials for Bladder Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 positive
2Skin Cancer
Saikrishna Gadde has run 6 trials for Skin Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 positive

Affiliated Hospitals

Image of trial facility.
University Of Tennessee - Knoxville
Image of trial facility.
University Of Tennessee

Clinical Trials Saikrishna Gadde is currently running

Image of trial facility.

Disitamab Vedotin + Pembrolizumab vs Chemotherapy

for Bladder Cancer

This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.
Recruiting2 awards Phase 3
Image of trial facility.

Immunotherapy + Targeted Therapy

for Genitourinary Cancers

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.
Recruiting1 award Phase 221 criteria

More about Saikrishna Gadde

Clinical Trial Related1 year of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Saikrishna Gadde has experience with
  • Carboplatin
  • Cisplatin
  • Nivolumab
  • Cabozantinib S-malate
  • Ipilimumab
  • Avelumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Saikrishna Gadde specialize in?
Is Saikrishna Gadde currently recruiting for clinical trials?
Are there any treatments that Saikrishna Gadde has studied deeply?
What is the best way to schedule an appointment with Saikrishna Gadde?
What is the office address of Saikrishna Gadde?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security